5. Conclusions
This study evaluated the GI tolerability of a novel SDC, oligomalt. Oligomalt was well tolerated when taken at a moderate (80 g/day) or high (180 g/day) dose, with no effect on stool frequency. An evolutive pattern with decreasing GI symptoms was seen with exposure over time, with normative scores being reached following 2–3 weeks of exposure to oligomalt. Given oligomalt’s healthier composition, it appears to be a potential viable alternative carbohydrate source for nutritional products, when also taking into account the implications for blood glucose, the insulin response, and overall metabolic health.